[Ip-health] Beyond the Obvious - Territorial Coverage of MPP_ViiV DTG License

Baker, Brook b.baker at northeastern.edu
Thu May 25 13:51:03 PDT 2017


https://www.ip-watch.org/2017/05/24/beyond-obvious-direct-indirect-territorial-coverage-mppviiv-voluntary-license-dolutegravir/
Beyond The Obvious - Direct And Indirect Territorial Coverage Of MPP/ViiV Voluntary License For Dolutegravir - Intellectual Property Watch<https://www.ip-watch.org/2017/05/24/beyond-obvious-direct-indirect-territorial-coverage-mppviiv-voluntary-license-dolutegravir/>
www.ip-watch.org
Pursuant to a license negotiated by the Medicines Patent Pool (MPP) with ViiV Healthcare (ViiV), an important new antiretroviral medicine, dolutegravir (DTG), will soon be available via generic competition in all low- and lower-middle-income countries, and a significant number of upper-middle-income countries as well. DTG is a highly recommended integrase inhibitor which highly effective, durable, inexpensive to produce, and relatively safe with few side effects. It is already an alternative WHO recommended first-line medicine and will probably become the global standard of care following trials on use of DTG to treat pregnant women and people with TB.[1] But until the MPP can succeed in getting inclusive licensing terms covering all low- and middle-income countries (LMICs), this unique clause in the MPP-ViiV license should be adopted in future licenses, as it is a best practice to date in terms of expansive coverage, writes Brook Baker.





Professor Brook K. Baker
Health GAP (Global Access Project) &
Northeastern U. School of Law, Program on Human Rights and the Global Economy
Honorary Research Fellow, Faculty of Law, Univ. of KwaZulu Natal, SA
400 Huntington Ave.
Boston, MA 02115 USA
(w) 617-373-3217
(c) 617-259-0760
(f) 617-373-5056
b.baker at neu.edu



More information about the Ip-health mailing list